140 related articles for article (PubMed ID: 35986816)
1. Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors.
Sheng IY; Gupta S; Reddy CA; Angelini D; Funchain P; Sussman TA; Sleiman J; Ornstein MC; McCrae K; Khorana AA
Target Oncol; 2022 Sep; 17(5):563-569. PubMed ID: 35986816
[TBL] [Abstract][Full Text] [Related]
2. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
3. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
Moik F; Chan WE; Wiedemann S; Hoeller C; Tuchmann F; Aretin MB; Fuereder T; Zöchbauer-Müller S; Preusser M; Pabinger I; Ay C
Blood; 2021 Mar; 137(12):1669-1678. PubMed ID: 33067632
[TBL] [Abstract][Full Text] [Related]
4. Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy.
Sheng IY; Gupta S; Reddy CA; Angelini D; Funchain P; Sussman TA; Sleiman J; Ornstein MC; McCrae K; Khorana AA
Target Oncol; 2021 Nov; 16(6):813-821. PubMed ID: 34741719
[TBL] [Abstract][Full Text] [Related]
5. Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study.
Iwai C; Jo T; Konishi T; Fujita A; Michihata N; Matsui H; Fushimi K; Yasunaga H
Cancer Immunol Immunother; 2023 Nov; 72(11):3581-3591. PubMed ID: 37540262
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors.
Ando Y; Hayashi T; Sugimoto R; Nishibe S; Ito K; Kawada K; Ikeda Y; Yamada S; Imaizumi K
Invest New Drugs; 2020 Aug; 38(4):1200-1206. PubMed ID: 31823160
[TBL] [Abstract][Full Text] [Related]
7. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
[TBL] [Abstract][Full Text] [Related]
8. Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors.
Alma S; Eloi D; Léa V; Julie C; Valérie M; Pierre G; Hilgers W; Philippe G; Christine Z; Philippe D
J Thromb Thrombolysis; 2022 Aug; 54(2):287-294. PubMed ID: 35396660
[TBL] [Abstract][Full Text] [Related]
9. Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor.
le Sève JD; Guédon AF; Bordenave S; Agard C; Connault J; Pistorius MA; Quéreux G; Espitia O
Thromb Haemost; 2023 Nov; 123(11):1049-1056. PubMed ID: 37257835
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma.
Swami U; Haaland B; Kessel A; Nussenzveig R; Maughan BL; Esther J; Sirohi D; Pal SK; Grivas P; Agarwal N
J Urol; 2021 Mar; 205(3):709-717. PubMed ID: 33080152
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.
Ramos JD; Casey MF; Crabb SJ; Bamias A; Harshman LC; Wong YN; Bellmunt J; De Giorgi U; Ladoire S; Powles T; Pal SK; Niegisch G; Recine F; Alva A; Agarwal N; Necchi A; Vaishampayan UN; Rosenberg JE; Galsky MD; Yu EY;
Cancer Med; 2017 Jan; 6(1):186-194. PubMed ID: 28000388
[TBL] [Abstract][Full Text] [Related]
12. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
13. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
14. Thromboembolism and Immune Checkpoint Blockade in Cancer Patients: An Old Foe for New Research.
Langouo Fontsa M; Aiello MM; Migliori E; Scartozzi M; Lambertini M; Willard-Gallo K; Solinas C
Target Oncol; 2022 Sep; 17(5):497-505. PubMed ID: 36102923
[TBL] [Abstract][Full Text] [Related]
15. Effects of Proton Pump Inhibitors on Survival Outcomes in Patients with Metastatic or Unresectable Urothelial Carcinoma Treated with Pembrolizumab.
Kunimitsu Y; Morio K; Hirata S; Yamamoto K; Omura T; Hara T; Harada K; Fujisawa M; Yano I
Biol Pharm Bull; 2022; 45(5):590-595. PubMed ID: 35491164
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
Patel JN; Jiang C; Hertz DL; Mulkey FA; Owzar K; Halabi S; Ratain MJ; Friedman PN; Small EJ; Carducci MA; Mahoney JF; Kelley MJ; Morris MJ; Kelly WK; McLeod HL
Cancer; 2015 Apr; 121(7):1025-31. PubMed ID: 25417775
[TBL] [Abstract][Full Text] [Related]
17. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
[TBL] [Abstract][Full Text] [Related]
18. Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.
Miller NJ; Khaki AR; Diamantopoulos LN; Bilen MA; Santos V; Agarwal N; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ; Shreck E; Assi H; Gartrell BA; Sankin A; Rodriguez-Vida A; Lythgoe M; Pinato DJ; Drakaki A; Joshi M; Isaacsson Velho P; Hahn N; Liu S; Alonso Buznego L; Duran I; Moses M; Jain J; Murgic J; Barata P; Tripathi A; Zakharia Y; Galsky MD; Sonpavde G; Yu EY; Lyman GH; Grivas P
J Urol; 2020 Jul; 204(1):63-70. PubMed ID: 31971495
[TBL] [Abstract][Full Text] [Related]
19. Urothelial carcinoma in the era of immune checkpoint inhibitors.
Khalife N; Chahine C; Kordahi M; Felefly T; Kourie HR; Saleh K
Immunotherapy; 2021 Aug; 13(11):953-964. PubMed ID: 34184561
[TBL] [Abstract][Full Text] [Related]
20. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
Khaki AR; Li A; Diamantopoulos LN; Miller NJ; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Koshkin V; Park J; Alva A; Bilen MA; Stewart T; Santos V; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Lythgoe MP; Pinato DJ; Murgic J; Fröbe A; Joshi M; Isaacsson Velho P; Hahn N; Alonso Buznego L; Duran I; Moses M; Barata P; Galsky MD; Sonpavde G; Yu EY; Shankaran V; Lyman GH; Grivas P
Eur Urol Oncol; 2021 Jun; 4(3):464-472. PubMed ID: 33423945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]